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Abstract
Mislocalization, aberrant processing and aggregation of TAR DNA-binding protein 43 (TDP-43) is found in the neurons
affected by two related diseases, amyotrophic lateral sclerosis (ALS) and frontotemporal lobe dementia (FTLD). These TDP-
43 abnormalities are seen when TDP-43 is mutated, such as in familial ALS, but also in FTLD, caused by null mutations in the
progranulin gene. They are also found in many patients with sporadic ALS and FTLD, conditions in which only wild type
TDP-43 is present. The common pathological hallmarks and symptomatic cross over between the two diseases suggest that
TDP-43 and progranulin may be mechanistically linked. In this study we aimed to address this link by establishing whether
overexpression of mutant TDP-43 or knock-down of progranulin in zebrafish embryos results in motor neuron phenotypes
and whether human progranulin is neuroprotective against such phenotypes. Mutant TDP-43 (A315T mutation) induced a
motor axonopathy characterized by short axonal outgrowth and aberrant branching, similar, but more severe, than that
induced by mutant SOD1. Knockdown of the two zebrafish progranulin genes, grna and grnb, produced a substantial
decrease in axonal length, with knockdown of grna alone producing a greater decrease in axonal length than grnb.
Progranulin overexpression rescued the axonopathy induced by progranulin knockdown. Interestingly, progranulin also
rescued the mutant TDP-43 induced axonopathy, whilst it failed to affect the mutant SOD1-induced phenotype. TDP-43 was
found to be nuclear in all conditions described. The findings described here demonstrate that progranulin is
neuroprotective in vivo and may have therapeutic potential for at least some forms of motor neuron degeneration.
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Introduction
The biological role of progranulin (PGRN) is incompletely
understood. It has been reported to be involved in development,
tumor growth, wound healing and inflammation, but its role in the
nervous system remains to be elucidated [1,2,3,4]. We have
previously demonstrated that PGRN has neurotrophic effects in
vitro, producing increased neurite lengths and neuron survival in
both cortical and motor neurons [5]. Its neuroprotective effect in
vivo is unexplored.
Null mutations in the PGRN gene are responsible for about a
third of hereditary FTLD, which itself represents about 40% of all
FTLD, the second most common form of dementia in patients
under 65 years of age [6,7,8]. These mutations produce
progranulin haplo-insufficiency, evident by decreased PGRN
levels in the cerebrospinal fluid and serum of patients with FTLD
caused by PGRN mutations [5,9,10]. The brains of patients with
progranulin mutations are characterized by nuclear and cytoplas-
mic inclusions that contain TDP-43 that is aberrantly cleaved,
phosphorylated and ubiquitinated [11,12]. Similar TDP-43
containing inclusions are also seen in the majority of patients
with sporadic FTLD [13].
Missense mutations in TDP-43, on the other hand, cause
amyotrophic lateral sclerosis (ALS) [14,15,16,17,18,19]. ALS is a
fatal motor neuron disease that is frequently accompanied by
frontal lobe dysfunction, and sometimes by full FTLD [20,21,22].
ALS is mostly sporadic (90%); mutations in TDP-43 explain about
5% of the hereditary forms [14]. The motor neurons of ALS
patients with TDP-43 mutations contain inclusions with abnor-
mally cleaved, phosphorylated and ubiquitinated TDP-43, similar
to those described for FTLD caused by progranulin mutations
[11]. Importantly, similar inclusions are also seen in sporadic ALS
patients, but not in patients with mutant SOD1-associated ALS
(which accounts for about 20% of familial ALS patients)[23,24].
The pathological and genetic links between FTLD and ALS
suggest an interaction between the molecular pathways through
which progranulin and TDP-43 act in the process of neurode-
generation. To study this interaction, we aimed to investigate the
effect of progranulin knock down or overexpression of wild type
and mutant TDP-43 on motor neuron outgrowth in the zebrafish.
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13368To investigate the role of PGRN in vivo we first examined the effect
of knocking down zebrafish PGRN protein using morpholinos
targeted to the grna and grnb genes, two fish orthologues of the
human gene. Both ATG and 59UTR morpholinos were used to
exclude off target effects, and 5-base pair mismatch morpholinos
were used as controls. We also aimed to confirm the effect of
mutant TDP-43 mRNA expression on motor axon outgrowth and
to test whether PGRN overexpression is protective against the
axonopathies induced by mutant TDP-43 and SOD1.
Results
Knockdown of zebrafish PGRN leads to a motor
axonopathy
Knockdown of grna and grnb separately with morpholino (MO)
directed to either the start codon (ATG MO) or sequence within
the 59 untranslated region (59 UTR morpholino) led to dose
dependent decreases in axonal length (Figure 1A and B). The
effect of knockdown of grna was more pronounced than that of
knockdown of grnb. The grna and grnb MO together had a
cumulative effect (Figure 1C). The axonal shortening induced by
grna knockdown (using the 59 UTR MO) was rescued by co-
expression of human PGRN mRNA (Figure 2A), indicating that
the effect was specifically caused by PGRN deficiency. Real time
PCR, following reverse transcription of RNA extracted from
24 hours post fertilization (hpf) zebrafish embryos injected with
PGRN mRNA (250ng/ml), confirmed the presence of human
PGRN mRNA following injection (Figure 2B). Further, a human
PGRN ELISA assay confirmed overexpression of human PGRN
protein in zebrafish embryos injected with PGRN mRNA
(Figure 2C).
Mt-TDP induces a motor axonopathy
Injection of wild type (Wt) and mutant (Mt, A315T) TDP-43
mRNA resulted in overexpression of human TDP-43, as indicated
by immunoblot of embryos 28 hours post injection (Figure 3A).
Protein produced by in vitro translation of the Wt TDP-43 mRNA
served as a positive control. Embryos overexpressing Wt TDP-43
exhibited modest axonal shortening and aberrant branching in
comparison with buffer injected embryos (Figure 3B). Neverthe-
Figure 1. PGRN knockdown results in reduced motor axon outgrowth. A) Knockdown of grna, by morpholino targeted to both the start
codon (ATG) and 59UTR region of zebrafish PGRN sequence, produced a dose dependent decrease in axonal length compared to mismatch Control
MO injected embryos.‘Significantly different from 200 mM Control MO, p,0.036; # significantly different from 50 mM MO, p,0.001; grna CO-MO
(ATG): n=41; grna CO-MO (UTR): n=20; grna ATG-MO, 50 mM: n=40, 100 mM: n=40, 200 mM: n=41; grna 59UTR-MO, 50 mM: n=27, 100 mM: n=28,
200 mM: n=14; Knockdown of grnb produced a similar, but more subtle, axonal shortening. * Significantly different from 600 mM Control MO,
p,0.038; # significantly different from 200 mM MO, p,0.05; grnb CO-MO (ATG): n=27; grnb CO-MO (UTR): n=10; grnb ATG-MO, 200 mM: n=40,
400 mM: n=36, 600 mM: n=41; grnb 59UTR-MO, 200 mM: n=9, 400 mM: n=12, 600 mM: n=12; B) The two MO used simultaneously had a cumulative
effect; * significantly different from Control MO a + b, p,0.002; # significantly different from all other groups p,0.0001. Buffer injected: n=20, CO-
MO (A + B): n=34, grnb MO: n=36, grna MO: n=36, grna + grnb MO: n=36. All bars represent mean 6 s.e.m.
doi:10.1371/journal.pone.0013368.g001
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PGRN. A) The decreased axonal length produced by knockdown of grna with a 59UTR MO was rescued by co-expression of PGRN mRNA.
* significantly different from grna CO MO, p,0.02;ˆ significantly different from grna MO + GFP, p,0.0001. Bars represent mean 6 s.e.m. Buffer
injected: n=20, CO-MO: n=15, CO-MO + PGRN: n=15, grna MO: n=15, grna MO + GFP: n=15, grna MO + PGRN: n=13. B) Real time PCR analysis of
cDNA reverse transcribed from RNA extracted from either non-injected or PGRN mRNA injected zebrafish embryos confirmed the presence of human
PGRN mRNA in injected embryos (*p,0.0001). C) Quantification of human PGRN protein levels in non-injected and PGRN mRNA injected zebrafish
embryos (24hpf) by ELISA confirmed the overexpression of human PGRN protein following PGRN mRNA injection (100 and 250 ng/ml). *Significantly
different from non-injected, p,0.043 (post-hoc Wilcoxon Signed Ranks test) following a significant Friedman Test, p=0.015.
doi:10.1371/journal.pone.0013368.g002
Figure 3. Overexpression of wild type (Wt) and mutant (Mt) TDP-43 mRNA produces motor axonopathies. A) Anti-V5 immunoblot
confirmed similar expression levels of Wt and Mt TDP-43 following TDP-43 mRNA injection. Protein produced by in vitro translation of the Wt TDP-43
mRNA served as a positive control. B) Overexpression of Wt TDP-43 produced modest axonal shortening (‘p,0.001) and aberrant branching
(‘p,0.001) in comparison with Buffer injection (n=61). Mt TDP-43 expression (600 ng/ml: n=37, 650 ng/ml: n=64, 700 ng/ml: n=26) produced a
more pronounced effect, resulting in significantly shorter axonal lengths (*p,0.001) and more embryos affected by aberrant branching (*p,0.001)
than Wt TDP-43 injected embryos (600 ng/ml: n=35, 650 ng/ml: n=59, 700 ng/ml: n=45).
doi:10.1371/journal.pone.0013368.g003
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decrease in axonal length compared with Wt TDP-43 expressing
embryos (Figure 3B), despite the embryos having equal body
lengths (p=0.62). Overexpression of mutant TDP-43 also
produced an outgrowth defect resulting in significantly more
branching in the Mt TDP-43 than Wt TDP-43 expressing
embryos when injected with 650 ng/ml mRNA. Signs of axono-
pathy (decreased axonal length and increased branching) were also
evident when Wt TDP-43 was injected at higher concentrations
(.650 ng/ml), decreasing the difference between Wt and Mt TDP-
43 expressing embryos at these concentrations.
Overexpression of human PGRN mRNA is protective
against the mutant TDP-43 induced axonopathy
To test for a neuroprotective effect of PGRN mRNA on the
mutant TDP-43 phenotype, human PGRN mRNA was co-
injected with Mt TDP-43 mRNA. Embryos co-injected with Mt
TDP-43 and GFP mRNA, as a control for non-specific effects of
RNA injection, exhibited similar axonal shortening and aberrant
branching as embryos expressing Mt TDP-43 alone. Co-
expression of PGRN mRNA with the Mt TDP-43 led to a
significant increase in axonal outgrowth length, approaching that
of Wt TDP-43 expressing embryos (Figure 4A and B). Co-
expression of PGRN mRNA also decreased the amount of
aberrant branching seen in Mt TDP-43 expressing embryos.
Conversely, overexpression of the same amount of PGRN mRNA
with Wt TDP-43 led to increased aberrant branching.
Human PGRN mRNA is not protective against the
axonopathy induced by mutant SOD1
Our laboratory has previously demonstrated that Mt SOD1
overexpression leads to motor axonopathies similar to that
described here for Mt TDP-43 [25]. Co-expression of PGRN
mRNA had no significant protective effect on the Mt SOD1
induced axonopathy (Figure 4B). Co-expression of PGRN with Wt
SOD1 led to an increase in aberrant branching, similar to that
seen when PGRN was co-expressed with Wt TDP-43.
TDP-43 localization in zebrafish embryos
Immunofluorescent staining of endogenous zebrafish TDP-43
and overexpressed human TDP-43 was performed in transversely
cryosectioned 30hpf embryos. TDP-43 immunoreactivity was
detected throughout the body of embryos, including in the ventral
spinal cord and forebrain. A nuclear staining pattern was found in
all embryos examined (non-injected, PGRN Morpholino injected,
Wt TDP-43, Mt TDP-43 and Mt SOD1) (Figure 5). As expected,
the intensity of TDP-43 immunofluorescence was greater in
embryos overexpressing human TDP-43.
Discussion
The data reported here demonstrate for the first time the
neurotrophic action of PGRN in vivo. Decreased PGRN levels,
produced by coinjected of morpholinos against zebrafish PGRN
gene homologues, grna and grnb, resulted in a substantial decrease
in axonal length. This decreased axonal outgrowth was produced
by morpholinos against both homologues simultaneously, as well
as separately. Further, use of morpholino acting in two different
manners to prevent translation, one that binds to the start codon of
the PGRN sequence and another that binds to a 59 untranslated
sequence, preventing the 40S ribosomal subunit from reaching the
start codon, led to the same effect. Non-specific effects of
morpholino injection were eliminated by comparison of all effects
with the morphology of embryos injected with the same
concentration of a control morpholino that contains the same
sequence but with five base pairs changed so that they do not bind
to the target sequence. The specificity of the morpholino effect was
Figure 4. Co-expression of PGRN rescues the axonopathy induced by Mt TDP-43 but not Mt SOD1. A) Staining of primary motor axons
with an anti-synaptic vesicle 2 revealed a decrease in axonal length and increase in aberrant branching in embryos expressing Mt TDP-43 compared
with Wt TDP-43. These signs of axonopathy were reduced by co-expression of human PGRN. B) Zebrafish embryos co-expressing Mt TDP-43 and
control mRNA (GFP) exhibited decreased axonal outgrowth and increased aberrant branching compared to embryos expressing Wt TDP and GFP
(p,0.001 and p=0.016, respectively). However, co-injection with the equivalent dosage of PGRN mRNA (250 ng/ml) rescued both axopathies
described (p,0.043). Mt SOD1 produced motor axon shortening (p,0.001) and increased branching (p,0.001) in comparison with Wt SOD1, as
described previously [25]. PGRN co-expression had no significant effect on the Mt SOD1 induced axonopathy but did increase aberrant branching in
Wt SOD1 injected embryos (p=0.006). ‘ indicates significantly different from buffer, * significantly different from ‘Wt + GFP’, and # significantly
different from ‘Mt + GFP’. Bars represent mean 6 s.e.m and the number of replicates per group is displayed below each bar.
doi:10.1371/journal.pone.0013368.g004
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through co-injection of human PGRN mRNA.
Our studies confirm a previous report that expression of mutant
TDP-43 induces a motor neuron axonopathy in zebrafish embryos
[26]. We further report that in addition to mutant TDP-43, high
levels of Wt TDP-43 also produce axon abnormalities. In larger
models, such as the mouse, overexpression of Wt TDP-43 has
been reported to result in neuronal loss, and in turn motor
dysfunction [27]. These results raise the possibility that altered
expression of Wt TDP-43 may also be disease causing in sporadic
ALS patients. Further studies are needed to elucidate if raised Wt
TDP-43 levels are present in sporadic ALS patients, perhaps due
to variations in the non-coding region of the gene [28].
Co-expression of PGRN mRNA proved to be protective against
the mutant TDP-43 induced axonopathy described. This co-
expression increased axonal outgrowth length to near normal
levels, and also decreased the degree of aberrant branching found
in mutant TDP-43 expressing embryos. Interestingly, PGRN
expression had no effect on the mutant SOD1 induced axono-
pathy and actually lead to a slight increase in branching within
wild type SOD1 expressing embryos, wherein axonal length is at
near maximal levels. The differential results for TDP-43 and
SOD1 suggest that the pathogenic mechanisms through which
TDP-43 and SOD1 lead to motor neuron degeneration may be
different, not only in their molecular pathways and morphological
hallmarks, but also in receptivity to protection by exogenous
neurotrophic factors. This is consistent with previous reports that
whilst TDP-43 pathology is present in the brains and spinal cords
of a majority of ALS patients [12,29], it is not present in patients
with SOD1 mutations [23,24].
We did not see abnormal TDP-43 sequestration following
PGRN knock down or mutant TDP-43 overexpression, consistent
with previous results in other animal models [26,30,31,32]. The
only effect of injection of TDP-43 mRNA on TDP-43 immuno-
reactivity was an increase in the intensity of the staining compared
to non-injected and PGRN MO injected embryos. These data
suggest that, at least in the zebrafish model, mutant TDP-43
expression and decreased PGRN levels can exert their harmful
effects without TDP-43 mislocalization occurring.
Our results demonstrate that PGRN is required for normal
axonal outgrowth in zebrafish embryos. We also report for the first
time the neuroprotective effect of supplemental PGRN levels
against mutant TDP-43 induced abnormalities. We thus suggest
that PGRN can have neurotrophic and neuroprotective effects in
vivo and that its therapeutic use for some forms of motor neuron
degeneration should be further investigated.
Methods
Constructs, mRNA production and morpholino
Antisense morpholinos (MO) against the start codon (ATG) or
59UTR of grna and grnb were designed and obtained from Gene
Tools (Philomath, OR, USA). Control morpholinos (CO MO),
comprised of the same sequence as their matching antisense MO
except for five mismatched bases, were also obtained from Gene
Tools. The sequences of the morpholino used are as follows:
Figure 5. TDP-43 localization in zebrafish embryos. Immunofluorescent staining of endogenous zebrafish TDP-43 and overexpressed human
TDP-43 was performed in transversely sectioned 30 hpf embryos in order to allow imaging of the spinal cord (shown in schematic diagram, A). TDP-
43 localization was nuclear in all embryos examined (B: non injected, C: PGRN MO injected, D: Wt TDP-43 injected, E: Mt TDP-43 (A315T) injected, and
F: co-expressing Mt TDP-43 and PGRN). The scale bar indicates a distance of 25 mm. Abbreviations: DSC, Dorsal spinal cord; VSC, Ventral spinal cord;
Myo, myotomes; NC, notochord; G, gut.
doi:10.1371/journal.pone.0013368.g005
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grna ATG CO MO: CAATTTTTCAGCACGTGAATTTCTG
grnb ATG MO: AGGCTATGAAAGCTGCACGCACCAT
grnb ATG CO MO: AGCCTATCAAACCTGCACCCAC-
GAT
grna 59 UTR: TTTTTGAGCAGGTGGATTTGTGAAC
grna 59 UTR CO MO: TATTTGACCACGTGCATTTGT-
CAAC
grnb 59 UTR: ACAGATGAAAAGCCATGAACGACTT
grnb 59 UTR CO MO: ACACATCAAAACCCATCAAC-
GAGTT
cDNA of wild type (Wt) human TDP-43 was purchased from
OpenBiosystems (Huntsville, AL) in the pCMVSport6.1 vector
and subcloned into the pcDNA4/V5-HisA vector (Invitrogen).
Mutagenesis was performed to produce the A315T mutation using
the Stratagene QuikChange Site-Directed Mutagenesis Kit with
the following primers:
A315T, Forward: GATGAACTTTGGTACGTTCAGCAT-
TAATCC
A315T, Reverse: GGATTAATGCTGAACGTACCAAAG-
TTCATC
The construct was linearized by StuI and mRNA was
transcribed from the linear transcript using the mMESSAGE
mMACHINE T7 Kit (Ambion, Huntingdon, UK) followed by
purification with a MEGAclear
TMKit (Ambion, Huntingdon,
UK). mRNA-concentration was determined using a NanoDrop
1000 spectrophotometer (Thermo Scientific, Waltham, MA). The
progranulin mRNA was similarly produced from a Topo TA
Cloning vector (Invitrogen), containing the full human PGRN
coding sequence, following linearization with HindIII.
Zebrafish maintenance and injection
All experiments were approved by, and performed in
accordance with the guidelines of, the Ethical Committee for
Animal Experimentation, K.U. Leuven (project approval
number P021/2010). Adult zebrafish (AB strain) and embryos
were maintained under standard laboratory conditions. Zebra-
fish embryo microinjectionsw e r em a d eu s i n gaF e m t o J e t
injection setup (Eppendorf, Hamburg, Germany). Each injection
was made in the 1–4 cell stage of the zebrafish embryo and
involved delivery of 2.14 nl of mRNA/MO solution, accom-
plished by an injection pressure of less than 4.5 psi, which
produced a droplet diameter of 160 mm on a micrometer.
E m b r y o sw e r et h e ns t o r e di nE 3s o l u t i o n( 5m MN a C l ,0 . 1 7m M
KCl, 0.33 mM CaCl2 and 0.33 mM MgSO4 and 0.1%
Methylene Blue) at 27.5–28.5uC.
Analysis of motor neuron outgrowth
At 30 hours post-fertilization (hpf), morphologically normal
zebrafish embryos were fixed in 4% paraformaldehyde in
phosphate-buffered saline (PBS) and immunostained using mouse
anti-synaptic vesicle 2 (1/200; Developmental Studies Hybridoma
Bank, University of Iowa, Iowa City, IO, USA) and secondary
Alexa Fluor 555 anti-mouse antibody (1/500; Molecular Probes,
Eugene, OR, USA) in order to visualize motor neurons. Observers
blind to injection and treatment conditions measured the axonal
length of the first five ventral motor axons after the yolk sac in
each embryo using Lucia software (version 4.9) and the average of
these five lengths was calculated for each embryo. Motor axons
were scored as affected by aberrant branching when two or more
axons per embryo branched at, or medial to, the ventral edge of
the notochord (all axons on each side of the embryo were
checked).
Real time PCR
A real time PCR was used to quantify the amount of human
progranulin mRNA delivered via injection into zebrafish embryos.
RNA was extracted from zebrafish embryos (50 embryos per
group, with three replicates per condition), using Trizol (Invitro-
gen, San Diego, CA) and isopropanol purification. cDNA was
obtained from the extracted RNA by reverse transcriptase PCR
(QuantiTect reverse transcription kit). The amount of human
proganulin DNA was quantified by real time PCR with the
following components:
Forward primer: 59 CGG AGG AGC CAG CTA CAG 39
Reverse primer: GAT59 GCC TGC TCA GTG TTG TG 39
and probe: FAM-CCC CTT CTG GAC AAA TG-NFQ
Thermal cycling was performed on a 7300 Sequence Detection
System (Applied Biosystems, Carlsbad, CA). All samples were
normalized to the level of 18S RNA.
Evidence of protein expression
Zebrafish embryos were dechorionated at 24–28 hpf and
transferred to a solution of E3 solution containing 1 mM PMSF.
The yolksac of the embryo was removed by suction through a
narrow glass pipette three times. The deyolked embryos were then
transferred to eppendorf tubes where the supernatant was
removed and 0.75 ml/embryo T-PER lysis buffer (Peirce, Rock-
ford, IL, USA) containing one tablet of Complete Protease
Inhibitors (Roche, Mannheim, Germany) per 25 ml and Phenyl-
methylsulfonyl fluoride (PMSF, final concentration 1 mM), was
added to lyse the sample. The samples were sonicated for 20 sec
and protein concentration was determined using the Micro-BSA
Protein Assay Reaction Kit (Pierce). For the TDP-43 immunoblot,
100 mg of zebrafish protein lysate and 5 mg of human Wt TDP-43
protein, produced by in vitro translation of the Wt TDP-43 mRNA
using a Retic Lysate IVT
TM kit (Ambion, Huntingdon, UK), was
separated on a SDS page gel and processed as described previously
[33]. Protein bound to the PVDF membrane was probed with an
antibody against the V5 tag (Invitrogen) that is fused to TDP-43 in
the injected mRNA, followed by anti-mouse HRP-coupled
secondary antibody (1:5000; Santa Cruz, Santa Cruz, CA,
USA). The protein bands were visualized by chemiluminescence
(ECL Western blot substrate, Peirce) and scanned on a
Biospectrum AC imaging system (UVP, CA).
Human PGRN protein levels were measured by sandwich
ELISA on protein lysates obtained in the same manner as
described above for immunoblot analysis. Multiple protein lysate
samples were prepared for each condition (non-injected: n=6,
100 ng/ml PGRN mRNA injected: n=6, and 250 ng/ml PGRN
mRNA injected: n=5), with each sample containing approxi-
mately forty embryos. For the ELISA assay, 96-well plates were
coated overnight at 4uC with 2 mg/ml anti-human monoclonal
PGRN antibody (R&D Systems) in phosphate-buffered saline
(PBS). After blocking with 2% Bovine Serum Albumin, protein
lysates diluted in PBS/0.004% Tween 20/0.1% BSA (or PBS
alone) were incubated at room temperature for 2 hours. All wells
were then incubated with anti-human biotinylated PGRN
antibody (R&D systems), followed by avidin/biotin horseradish
peroxidase complex (Vector Laboratories, Burlingame, CA,
diluted 1:100). The chromogenic reagent o-phenylenediamine
(OPD) was applied to all wells of the plate (30 min, room
temperature) and the resulting color reaction was stopped with
4MH 2SO4. The plate was read on a VictorX3 plate reader
(Perkin Elmer, Waltham, MA) at an absorbance of 490 nm. The
resultant progranulin protein concentrations were normalized to
the total protein content of the sample, and graphed normalized to
Progranulin is Neuroprotective
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concentration of the non-injected sample).
TDP-43 immunofluorescence in zebrafish sections
To allow immunofluorescent staining of sectioned zebrafish
embryos 30hpf embryos were fixed in 4% paraformaldehyde
overnight, followed by overnight cryoprotection incubation in
20% sucrose. Embryos were then mounted in Tissue-Tek OCT
compound (Sakura Finetek, Zoeterwoude, The Netherlands),
frozen and transversely cryosectioned at a thickness of 20 mm.
Antigen retrieval was performed by boiling sections in sodium
citrate buffer (10 mM sodium citrate, 0.05% Tween 20, pH 6.0)
for 30 min. Non-specific staining was blocked by incubation of
sections in blocking solution (PBS containing 5% normal horse
serum, 5% bovine serum albumin and 0.1% Triton X-100) for
1 hr. Sections were then incubated in primary antibody (1/200,
polyclonal rabbit anti-TDP-43, ProteinTech Group Inc., Chicago,
IL) diluted in PBS with 0.1% Triton X-100. Incubation with a
fluorescent secondary antibody (anti-rabbit Alexa Fluor 488
antibody, 1/500; Molecular Probes, Eugene, OR, USA) followed.
Statistical analysis
Statistics were performed using SPSS 16.0. Axonal lengths were
analyzed with one-way ANOVA followed by a Bonferroni post-
hoc test. For comparison of the rate of aberrant branching
(percentage data) chi-squared tests were used. Real time PCR data
was also analyzed with one-way ANOVA. The human PGRN
protein concentration data obtained from an ELISA assay was
analyzed with a non-parametric Friedman repeated measures test,
followed by a post-hoc Wilcoxon signed ranks test. All P-values
,0.05 were taken as significant.
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